Raptor Pharmaceutical Corp.
NOVATO, Calif., 2012-05-03 12:30 CEST (GLOBE NEWSWIRE) --
Raptor Pharmaceutical Corp. (´Raptor´ or the ´Company´) (Nasdaq:RPTP), today
announced that Christopher M. Starr, Ph.D., Chief Executive Officer of Raptor,
will present an overview of the Company at two investor conferences in May.
The conference presentation schedule is as follows:
Deutsche Bank 37th Annual Healthcare Conference
May 8, 2012 at 1:30pm ET
InterContinental, Boston, MA
Bank of America Merrill Lynch 2012 Healthcare Conference
May 16, 2012 at 10:00am
Encore at the Wynn, Las Vegas, NV
A live audio webcast and 14-day archive of the Bank of America presentation
will be available at http://ir.raptorpharma.com/events.cfm
About Raptor Pharmaceutical Corp.
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) (´Raptor´) seeks to research,
produce, and deliver medicines that improve life for patients with severe, rare
disorders. Raptor currently has product candidates in clinical development
designed to potentially treat nephropathic cystinosis, Non-alcoholic
Steatohepatitis (´NASH´), Huntington´s Disease (´HD´), aldehyde dehydrogenase
deficiency (´ALDH2´), and thrombotic disorder.
Raptor´s preclinical programs are based upon bioengineered novel drug
candidates and drug-targeting platforms derived from the human
receptor-associated protein and related proteins that are designed to target
cancer and infectious diseases.
For additional information, please visit www.raptorpharma.com.
The Raptor Pharmaceutical Corp. logo is available at
CONTACT: Trout Group (investors)
EVC Group (media)
News Source: NASDAQ OMX
03.05.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP´s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Company: Raptor Pharmaceutical Corp.
End of Announcement DGAP